Drug Profile


Alternative Names: AGY-94806; Cutamesine dihydrochloride; Msc-1; SA-4503

Latest Information Update: 23 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Santen Pharmaceutical
  • Developer Ms Science; Santen Pharmaceutical
  • Class Antidepressants; Neuroprotectants; Nootropics; Piperazines; Small molecules
  • Mechanism of Action Sigma-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Amyotrophic lateral sclerosis; Retinitis pigmentosa
  • Discontinued Major depressive disorder; Stroke; Vascular dementia

Most Recent Events

  • 10 Mar 2014 Preclinical trials in Amyotrophic lateral sclerosis in Japan (PO)
  • 01 Dec 2010 Cutamesine is still in phase IIa development for Stroke and Depression
  • 12 Mar 2008 M's Science Corporation and Eisai enter into an option agreement for SA 4503
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top